Search Results - "Asatsuma-Okumura T"

Myelodysplastic Syndrome With Complex Chromosomal Karyotype Abnormalities Complicated by Multiple Intestinal Perforations: A Case Report and Literature Review.

Authors: Niu, Zhan-Yue Zhu, Ming-Fei Tao, Ming et al.

Source: Case Reports in Gastrointestinal Medicine. 1/8/2026, Vol. 2026, p1-7. 7p.

Lysosomal degradation of PD-L1 is associated with immune-related adverse events during anti-PD-L1 immunotherapy in NSCLC patients.

Authors: Kashiwada T Takano R Ando F et al.

Source: Frontiers in pharmacology [Front Pharmacol] 2024 May 10; Vol. 15, pp. 1384733. Date of Electronic Publication: 2024 May 10 (Print Publication: 2024).

Publication Type: Journal Article

Journal Info: Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE

Combination of plasma MMPs and PD-1-binding soluble PD-L1 predicts recurrence in gastric cancer and the efficacy of immune checkpoint inhibitors in non-small cell lung cancer.

Authors: Ando F Kashiwada T Kuroda S et al.

Source: Frontiers in pharmacology [Front Pharmacol] 2024 May 07; Vol. 15, pp. 1384731. Date of Electronic Publication: 2024 May 07 (Print Publication: 2024).

Publication Type: Journal Article

Journal Info: Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE

Synergistic targeting of the ARID2-MYC axis by pomalidomide and panobinostat overcomes intrinsic IMiD resistance in multiple myeloma.

Authors: Yamamoto J Asatsuma-Okumura T Ito T et al.

Source: Scientific reports [Sci Rep] 2026 Feb 05; Vol. 16 (1). Date of Electronic Publication: 2026 Feb 05.

Publication Type: Journal Article

Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Thalidomide-induced limb malformations: an update and reevaluation.

Authors: Collins MD Scott WJ

Source: Archives of toxicology [Arch Toxicol] 2025 May; Vol. 99 (5), pp. 1643-1747. Date of Electronic Publication: 2025 Apr 08.

Publication Type: Journal Article; Review

Journal Info: Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 0417615 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0738 (Electronic) Linking ISSN: 03405761 NLM ISO Abbreviation: Arch Toxicol Subsets: MEDLINE

Thalidomide-Based PROTACs: A Viable Strategy Against Trypanosomatids?

Authors: Manarin, Romina Frattini, Gianfranco Alonso, Victoria L. et al.

Source: Drugs & Drug Candidates. Dec2025, Vol. 4 Issue 4, p55. 17p.

This result is not displayed to guests.
Login for full access.

Single-Cell Sequencing Reveals Thalidomide-Induced Teratogenicity in Zebrafish via Endoplasmic Reticulum Stress and Dysregulated Angiogenic Signaling.

Authors: Zhao J Song T

Source: The Journal of craniofacial surgery [J Craniofac Surg] 2026 Mar-Apr 01; Vol. 37 (3-4), pp. 746-752. Date of Electronic Publication: 2025 Jun 23.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 9010410 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1536-3732 (Electronic) Linking ISSN: 10492275 NLM ISO Abbreviation: J Craniofac Surg Subsets: MEDLINE

From immunomodulators (IMiDs) to cereblon E3 ligase modulator (CELMoDs): the evolution of cereblon modulators in lymphoma therapy.

Authors: Saha, Aditi Jhaveri, Khushali Perini, Guilherme F. et al.

Source: Leukemia & Lymphoma. Jun2026, Vol. 67 Issue 7, p1479-1491. 13p.

Plant-Derived Compounds as Potential Sensitizers to Immunotherapy in Melanoma.

Authors: Bătrîna, Oana Negrea-Ghiulai, Roxana Suciu, Liana et al.

Source: International Journal of Molecular Sciences. May2026, Vol. 27 Issue 10, p4423. 65p.

Comprehensive Search for Genes Involved in Thalidomide Teratogenicity Using Early Differentiation Models of Human Induced Pluripotent Stem Cells: Potential Applications in Reproductive and Developmental Toxicity Testing.

Authors: Kato, Yu Inaba, Takeshi Shinke, Koudai et al.

Source: Cells (2073-4409). Feb2025, Vol. 14 Issue 3, p215. 16p.

Efficacy of Adding Immune Checkpoint Inhibitors to Chemotherapy Plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-Analysis of Randomized Controlled Trials.

Authors: Ando, Fumihiko Matsuda, Akihisa Miyamoto, Yuji et al.

Source: Cancers. Aug2025, Vol. 17 Issue 15, p2538. 13p.

Thalidomide: History of Research and Perspectives for Its Medical Use (Review).

Authors: Kurkin, D. V. Bakupin, D. A. Morkovin, E. I. et al.

Source: Pharmaceutical Chemistry Journal. Oct2024, Vol. 58 Issue 7, p1001-1010. 10p.

Targeting neuroinflammation: 3-monothiopomalidomide a new drug candidate to mitigate traumatic brain injury and neurodegeneration.

Authors: Hsueh, Shih Chang Parekh, Pathik Batsaikhan, Buyandelger et al.

Source: Journal of Biomedical Science. 6/16/2025, Vol. 32 Issue 1, p1-29. 29p.

Molecular Glue Degraders Redefining Targeted Therapies From Discovery to Therapeutic Applications.

Authors: Wen, Jinfeng Yu, Jingtian Wen, Wuqiang et al.

Source: Medcomm: Oncology. Mar2026, Vol. 5 Issue 1, p1-44. 44p.

Advances in molecular glue degraders for targeted protein degradation: Focus on NEK7, WEE1, CDK2, GSPT1 and VAV1.

Authors: Cheng, Binbin Wang, Yaping Hong, Yimeng et al.

Source: Asian Journal of Pharmaceutical Sciences. Feb2026, Vol. 21 Issue 1, p1-15. 15p.

A Novel Paradigm for Targeting Challenging Targets: Advancing Technologies and Future Directions of Molecular Glue Degraders.

Authors: Zhang, Yifan Li, Linlin Xu, Jiajia et al.

Source: Molecules. Feb2026, Vol. 31 Issue 3, p459. 40p.

POT, an optogenetics-based endogenous protein degradation system.

Authors: Chen, Yunyue Wang, Siyifei Zhang, Luhao et al.

Source: Communications Biology. 3/18/2025, Vol. 8 Issue 1, p1-10. 10p.

Plasma Cell Myeloma: Biochemical Insights into Diagnosis, Treatment, and Smart Nanocarrier-Based Therapeutic Development.

Authors: Muñoz, Lizeth Geraldine Luna, Sixta Palencia Chamorro, Andrés Felipe

Source: Pharmaceutics. Dec2025, Vol. 17 Issue 12, p1570. 42p.

BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma.

Authors: Yan, Yuhan Tu, Yixuan Cheng, Qian et al.

Source: Journal of Translational Medicine. 11/29/2024, Vol. 22 Issue 1, p1-13. 13p.